Dongwha Pharm Invests 3 Billion KRW in AI Healthcare Company Vuno
[Asia Economy Reporter Hyun-ui Cho] Dongwha Pharm announced on the 14th that it has made a 3 billion KRW equity investment in Vuno, a medical artificial intelligence (AI) healthcare solution company.
Vuno is a company that develops AI-based diagnostic support and disease prediction software for medical purposes. It gained attention as the first in Korea to receive approval for clinical trials of AI medical devices based on biometric signals.
Over the past three years, Dongwha Pharm has actively invested in various bio-venture companies with the goal of diversifying its business based on the latest healthcare trends. In addition to Vuno, the company has invested in aesthetic bio company Zetema, mobile healthcare company Philosis, healthcare startup VBV, medical device manufacturer LivesMed, crowdfunding platform Crowdy, and accelerator Krypton.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- Blue House Thanks Labor and Management of Samsung Electronics for Their Magnanimous Decision
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Ki-hwan, CEO of Dongwha Pharm, said, “We have high expectations for investing in Vuno, a recently spotlighted AI healthcare solution company,” and added, “Dongwha Pharm plans to continuously establish various business partnerships to grow as a leading company in the healthcare field.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
